Versantis is a clinical-stage company developing disruptive orphan drugs for liver and pediatric diseases. Our lead candidate, VS-01, uses a disruptive liposomes-based technology to treat adults with decompensated cirrhosis and/or ACLF effectively (Versantis’ most advanced program), as well as children with rare hyperammonemic crisis caused by genetic disorders. VS-01 is currently being evaluated in first-in-human clinical trials, and Versantis recently closed a USD 16m Series B financing round to advance to Ph2a clinical development. VS-01 was granted two orphan drug designations by the EMA and the FDA, which will streamline its clinical development pathway.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):